68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer.
Clin Nucl Med
; 44(9): e535-e536, 2019 Sep.
Article
em En
| MEDLINE
| ID: mdl-31246685
ABSTRACT
Ga-labeled prostate-specific membrane antigen inhibitors and Ga-labeled gastrin-releasing peptide receptor antagonists showed interesting results for staging biochemically recurrent prostate cancer. In this case, Ga-prostate-specific membrane antigen-617 PET/CT, Ga-RM2 PET/CT, and F-choline PET/CT were performed in a patient (66-year-old man, prostate-specific antigen = 6.7 ng/mL) with biopsy-proven Gleason 9 (5 + 4) prostate cancer, candidate for radical prostatectomy and lymph node dissection.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oligopeptídeos
/
Neoplasias da Próstata
/
Colina
/
Dipeptídeos
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
/
Radioisótopos de Gálio
/
Compostos Heterocíclicos com 1 Anel
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article